SAFETY DATA SHEET



IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : IMAP Lyophilized Peptide Substrate (50,000 test points)

Product type : Solid.

Other means of : Not available. identification

Product part number

: F7136 / R7169 / R7170 / R7171 / R7172 / R7230 / R7231 / R7232 / R7233 / R7234 / R7255 / R7256 / R7257 / R7258 / R7259 / R7270 / R7271 / R7272 / R7273 / R7274 / R7275 / R7276 / R7277 / R7278 / R7293 / R7295 / R7300 / R7301 / R7302 / R7303 / R7304 / R7305 / R7306 / R7307 / R7308 / R7309 / R7310 / R7311 / R7312 / R7313 / R7314 / R7315 / R7316 / R7317 / R7318 / R7319 / R7320 / R7321 / R7322 / R7323 / R7324 / R7330 / R7331 / R7332 / R7333 / R7334 / R7335 / R7336 / R7337 / R7338 / R7339 / R7340 / R7341 / R7342 / R7343 / R7344 / R7345 / R7346 / R7347 / R7348 / R7351 / R7352 / R7353 / R7354 / R7355 / R7356 / R7357 / R7358 / R7359 / R7360 / R7361 / R7369 / R7370 / R7371 / R7372 / R7373 / R7374 / R7375 / R7376 / R7377 / R7378 / R7379 / R7380 / R7381 / R7382 / R7383 / R7384 / R7385 / R7435 / R7475 / R7477 / RP7501 / RP7502 / RP7503 / RP7504 / RP7505 / RP7506 / RP7507 / RP7508 / RP7509 / RP7510 / RP7511 / RP7512 / RP7513 / RP7514 / RP7515 / RP7516 / RP7517 / RP7518 / RP7519 / RP7520 / RP7521 / RP7522 / RP7523 / RP7524 / RP7525 / RP7526 / RP7527 / RP7528 / RP7529 / RP7530 / RP7531 / RP7532 / RP7533 / RP7534 / RP7535 / RP7536 / RP7537 / RP7538 / RP7539 / RP7540 / RP7541 / RP7542 / RP7543 / RP7545 / RP7546 / RP7548 / RP7549 / RP7553 / RP7554 / RP7555 / RP7556 / RP7557 / RP7558 / RP7559 / RP7560 / RP7561 / RP7562 / RP7563 / RP7564 / RP7565 / RP7566 / RP7567 / RP7568 / RP7569 / RP7570 / RP7571 / RP7572 / RP7573 / RP7574 / RP7575 / RP7576 / RP7577 / RP7578 / RP7579 / RP7580 / RP7582 / RP7583 / RP7584 / RP7585 / RP7586 / RP7587 / RP7588 / RP7589 / RP7590 / RP7591 / RP7592 / RP7593 / RP7594 / RP7595 / RP7596 / RP7597 / RP7598 / RP7599 / RP7600 / RP7601 / RP7602 / RP7603 / RP7604 / RP7606 / RP7607 / RP7608 / RP7609 / RP7610 / RP7611 / RP7612 / RP7613 / RP7614 / RP7615 / RP7616 / RP7617 / RP7618 / RP7619 / RP7620 / RP7621 / RP7622 / RP7623 / RP7624 / RP7625 / RP7626 / RP7627 / RP7628 / RP7629 / RP7630 / RP7631 / RP7632 / RP7633 / RP7634 / RP7635 / RP7636 / RP7637 / RP7638 / RP7639 / RP7640 / RP7641 / RP7642 / RP7643 / RP7644 / RP7645 / RP7646 / RP7647 / RP7648 / RP7649 / RP7650 / RP7651 / RP7652 / RP7653 / RP7654 / RP7655

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : For R&D use only.

Area of application: Professional applications.

Uses advised against

None identified.

1.3 Details of the supplier of the safety data sheet

Molecular Devices (Austria) GmbH Urstein Süd 17 5412 Puch / Hallein AUSTRIA

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 1/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 1: Identification of the substance/mixture and of the company/undertaking

e-mail address of person responsible for this SDS

: msdsinguiry@moldev.com

1.4 Emergency telephone number

National advisory body/Poison Centre

Telephone number : CHEMTREC (24 hours): 1-800-424-9300 (USA/Canada),

+1 703-527-3887 (Outside USA/Canada)

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

Ingredients of unknown

toxicity

: 10 percent of the mixture consists of component(s) of unknown acute oral toxicity 28 percent of the mixture consists of component(s) of unknown acute dermal toxicity 29.1 percent of the mixture consists of component(s) of unknown acute inhalation

toxicity

Ingredients of unknown

ecotoxicity

: Contains 28% of components with unknown hazards to the aquatic environment

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

Disposal : Not applicable.

Supplemental label

elements

: Safety data sheet available on request.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Special packaging requirements

Containers to be fitted

with child-resistant

: Not applicable.

fastenings

Tactile warning of danger : Not applicable.

2.3 Other hazards

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 2/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 2: Hazards identification

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification

: None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
sucrose	REACH #: Annex IV EC: 200-334-9 CAS: 57-50-1	≤10	Not classified.	[2]
Albumins, blood serum	EC: 232-936-2 CAS: 9048-46-8	≤10	Acute Tox. 4, H302	[1]
trometamol	EC: 201-064-4 CAS: 77-86-1	≤3	Skin Irrit. 2, H315 Eye Irrit. 2, H319	[1]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation

occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing.

Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be

kept under medical surveillance for 48 hours.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and

shoes. Get medical attention if symptoms occur.

Ingestion : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless

directed to do so by medical personnel. Get medical attention if symptoms occur.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 3/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 4: First aid measures

Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing

media

: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing

media

: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: No specific fire or explosion hazard.

Hazardous thermal decomposition products

 Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

sulfur oxides

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

For emergency responders

: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 4/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 6: Accidental release measures

6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

Small spill

: Move containers from spill area. Vacuum or sweep up material and place in a designated, labelled waste container. Dispose of via a licensed waste disposal contractor.

Large spill

: Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Vacuum or sweep up material and place in a designated, labelled waste container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections

See Section 1 for emergency contact information.
 See Section 8 for information on appropriate personal protective equipment.
 See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
sucrose	EH40/2005 WELs (United Kingdom (UK), 1/2020). STEL: 20 mg/m³ 15 minutes. TWA: 10 mg/m³ 8 hours.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 5/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 8: Exposure controls/personal protection

Recommended monitoring procedures

: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Type	Exposure	Value	Population	Effects
trometamol	DNEL	Long term Oral	8.3 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	29 mg/m³	General population	Systemic
	DNEL	Long term Dermal	83.3 mg/ kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	117.5 mg/ m³	Workers	Systemic
	DNEL	Long term Dermal	166.7 mg/ kg bw/day	Workers	Systemic

PNECs

No PNECs available

8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 6/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 8: Exposure controls/personal protection

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Solid.

Colour Not available. : Not available. Odour Not available. **Odour threshold** pH : Not available. Melting point/freezing point : Not available. Initial boiling point and boiling : Not available.

range

: Not applicable. Flash point Not available. **Evaporation rate** Flammability (solid, gas) : Not available. : Not applicable.

Upper/lower flammability or explosive limits

: Not available. Vapour pressure : Not applicable. Vapour density Not available. Relative density : Not available. Solubility(ies) Partition coefficient: n-octanol/ : Not applicable.

water

: Not applicable. **Auto-ignition temperature** : Not available. **Decomposition temperature** Not applicable. **Viscosity** Not available. **Explosive properties** Not available. **Oxidising properties**

9.2 Other information

Physical/chemical properties comments

: No additional information.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version: 3.01 7/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 10: Stability and reactivity

10.1 Reactivity

: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability

: The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerisation will not occur.

10.4 Conditions to avoid

: No specific data.

10.5 Incompatible materials

: Reactive or incompatible with the following materials: oxidising materials.

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
trometamol		Rat - Male, Female	>5000 mg/kg	-
	LD50 Oral	Rat - Female	>5000 mg/kg	-

Conclusion/Summary

: Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
IMAP Lyophilized Peptide Substrate (50,000 test points)	5555.6	N/A	N/A	N/A	N/A
Albumins, blood serum	500	N/A	N/A	N/A	N/A

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
trometamol	Skin - Moderate irritant	Rabbit	-	25 %	-
	Skin - Severe irritant	Rabbit	-	500 mg	-

Conclusion/Summary

: Not available.

Sensitisation

Conclusion/Summary

: Not available.

Mutagenicity

Conclusion/Summary

: Not available.

Carcinogenicity

Conclusion/Summary

: Not available.

Reproductive toxicity

Date of issue/Date of revision : 05/11/2021 Date of previous issue :11/12/2020 Version : 3.01 8/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 11: Toxicological information

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes

of exposure

: Routes of entry anticipated: Oral, Dermal, Inhalation.

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate

effects

: Not available.

Potential delayed effects

: Not available.

Long term exposure

Potential immediate

: Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

General : No known significant effects or critical hazards.
 Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

Other information : Not available.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 9/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
trometamol	Acute EC50 >980 mg/l Fresh water	Daphnia - Daphnia magna	48 hours
	Acute NOEC 520 mg/l Fresh water	Daphnia - Daphnia magna	48 hours

Conclusion/Summary: Not available.

12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
trometamol	OECD 301F Ready Biodegradability - Manometric Respirometry Test	,	30 mg/l	-

Conclusion/Summary: Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
trometamol	-	-	Readily

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
trometamol	-2.31	-	low

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible.

Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 10/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 13: Disposal considerations

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions

: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

14.6 Special precautions for user

Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous

substances, mixtures and articles

Substances requiring

: Not applicable.

labelling

Other EU regulations

Europe inventory : All components are listed or exempted.

Ozone depleting substances (1005/2009/EU)

Date of issue/Date of revision : 05/11/2021 Date of previous issue :11/12/2020 Version : 3.01 11/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 15: Regulatory information

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

15.3 Registration status

: Mixture. Information concerning the substance : Contact local supplier or distributor.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/20081

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

vPvB = Very Persistent and Very Bioaccumulative

Key literature references and sources for data

: Regulation (EC) No. 1272/2008 [CLP]; European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR), concluded in Geneva on 30 September 1957 plus amendments (Uniform text: Journal of Laws 27/2009 pos. 162 plus amendments); European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways (ADN); Occupational exposure limits; International regulations

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

Full text of abbreviated H statements

Date of issue/Date of revision : 05/11/2021 Date of previous issue :11/12/2020 Version: 3.01 12/13

IMAP Lyophilized Peptide Substrate (50,000 test points)

SECTION 16: Other information

H302	Harmful if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.

Full text of classifications [CLP/GHS]

Acute Tox. 4	ACUTE TOXICITY - Category 4
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2

Training advice : Ensure operatives are trained to minimise exposures. Training staff on good practice.

Date of issue/ Date of

revision

: 05/11/2021

Date of previous issue : 11/12/2020

Version : 3.01

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Date of issue/Date of revision : 05/11/2021 Date of previous issue : 11/12/2020 Version : 3.01 13/13